JP2024520435A - 組み合わせ療法を用いて多発性骨髄腫を治療する方法 - Google Patents

組み合わせ療法を用いて多発性骨髄腫を治療する方法 Download PDF

Info

Publication number
JP2024520435A
JP2024520435A JP2023572827A JP2023572827A JP2024520435A JP 2024520435 A JP2024520435 A JP 2024520435A JP 2023572827 A JP2023572827 A JP 2023572827A JP 2023572827 A JP2023572827 A JP 2023572827A JP 2024520435 A JP2024520435 A JP 2024520435A
Authority
JP
Japan
Prior art keywords
days
day
compound
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520435A5 (https=
Inventor
セサル マシアグ，パウロ
ペルーゾ，テレーザ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Bristol Myers Squibb Co
Original Assignee
Celgene Corp
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Bristol Myers Squibb Co filed Critical Celgene Corp
Publication of JP2024520435A publication Critical patent/JP2024520435A/ja
Publication of JP2024520435A5 publication Critical patent/JP2024520435A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023572827A 2021-05-27 2022-05-26 組み合わせ療法を用いて多発性骨髄腫を治療する方法 Pending JP2024520435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194026P 2021-05-27 2021-05-27
US63/194,026 2021-05-27
PCT/US2022/031055 WO2022251441A1 (en) 2021-05-27 2022-05-26 Methods of treating multiple myeloma using combination therapy

Publications (2)

Publication Number Publication Date
JP2024520435A true JP2024520435A (ja) 2024-05-24
JP2024520435A5 JP2024520435A5 (https=) 2025-05-30

Family

ID=82067750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572827A Pending JP2024520435A (ja) 2021-05-27 2022-05-26 組み合わせ療法を用いて多発性骨髄腫を治療する方法

Country Status (11)

Country Link
US (1) US20240252487A1 (https=)
EP (1) EP4347037A1 (https=)
JP (1) JP2024520435A (https=)
KR (1) KR20240013793A (https=)
CN (1) CN117440828A (https=)
AU (1) AU2022282372A1 (https=)
BR (1) BR112023022679A2 (https=)
CA (1) CA3215840A1 (https=)
IL (1) IL307681A (https=)
MX (1) MX2023012911A (https=)
WO (1) WO2022251441A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
WO2020146441A1 (en) 2019-01-09 2020-07-16 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
FI3908281T3 (fi) 2019-01-09 2024-10-01 Celgene Corp Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
SG11202107439XA (en) 2019-01-09 2021-08-30 Celgene Corp Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same

Also Published As

Publication number Publication date
AU2022282372A1 (en) 2023-11-02
WO2022251441A1 (en) 2022-12-01
BR112023022679A2 (pt) 2024-01-23
CA3215840A1 (en) 2022-12-01
EP4347037A1 (en) 2024-04-10
IL307681A (en) 2023-12-01
US20240252487A1 (en) 2024-08-01
MX2023012911A (es) 2023-11-08
CN117440828A (zh) 2024-01-23
KR20240013793A (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
JP7258009B2 (ja) 抗増殖化合物及びその使用方法
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
JP7408396B2 (ja) 併用療法
US12240903B2 (en) Biomarkers for determining the effectiveness of immune checkpoint inhibitors
JP2020517652A5 (https=)
JP2019011376A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
Kubo et al. Study protocol: Phase-Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors
JP2018138570A (ja) 癌の治療のためのａｍｇ９００の使用
EP3914257B1 (en) Combination of a bcl-2/bcl-xl inhibitor with osimertinib
UA126313C2 (uk) Комбінована терапія
WO2022109601A1 (en) Active cancer immunotherapy by immune modulation via globo series antigens
JP2024520435A (ja) 組み合わせ療法を用いて多発性骨髄腫を治療する方法
TW202120085A (zh) 抗ccr4抗體抵抗性之癌症的治療劑
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
EP4493185A1 (en) Treatment of breast cancer with amcenestrant
JP2025533900A (ja) エストロゲン受容体媒介性障害を治療する方法
WO2024015506A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
CN118804747A (zh) 用安森司群治疗乳腺癌
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
KR20210097139A (ko) 데비미스타트를 사용하는 급성 골수성 백혈병을 치료하기 위한 치료적 방법 및 조성물
TW201540296A (zh) 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428